Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
Roy F Chemaly, Andrew J Ullmann, Susanne Stoelben, Marie Paule Richard, Martin Bornhäuser, Christoph Groth, Hermann Einsele, Margarida Silverman, Kathleen M Mullane, Janice Brown, Horst Nowak, Katrin Kölling, Hans P Stobernack, Peter Lischka, Holger Zimmermann, Helga Rübsamen-Schaeff, Richard E Champlin, Gerhard Ehninger, AIC246 Study Team, Matthias Stelljes, Nicholaus Kröeger, Luke Akard, Peter Dreger, Martin Kaufmann, Michael Maris, George Alangaden, Hannes Wandt, Hartmut Bertz, Drew Winston, John Hiemenz, Tulio Rodriguez, Per Ljungman, David Goldsmith, George Dresser, Claudia Schmoor, Roy F Chemaly, Andrew J Ullmann, Susanne Stoelben, Marie Paule Richard, Martin Bornhäuser, Christoph Groth, Hermann Einsele, Margarida Silverman, Kathleen M Mullane, Janice Brown, Horst Nowak, Katrin Kölling, Hans P Stobernack, Peter Lischka, Holger Zimmermann, Helga Rübsamen-Schaeff, Richard E Champlin, Gerhard Ehninger, AIC246 Study Team, Matthias Stelljes, Nicholaus Kröeger, Luke Akard, Peter Dreger, Martin Kaufmann, Michael Maris, George Alangaden, Hannes Wandt, Hartmut Bertz, Drew Winston, John Hiemenz, Tulio Rodriguez, Per Ljungman, David Goldsmith, George Dresser, Claudia Schmoor
Abstract
Background: Cytomegalovirus (CMV) infection is a leading cause of illness and death in patients who have undergone allogeneic hematopoietic-cell transplantation. Available treatments are restricted by clinically significant toxic effects and drug resistance.
Methods: In this phase 2 study, we evaluated the effect of letermovir (also known as AIC246), a new anti-CMV drug with a novel mechanism of action, on the incidence and time to onset of prophylaxis failure in CMV-seropositive recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donors. From March 2010 through October 2011, we randomly assigned 131 transplant recipients in a 3:1 ratio to three sequential study cohorts according to a double-blind design. Patients received oral letermovir (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 weeks after engraftment. The primary end point was all-cause prophylaxis failure, defined as discontinuation of the study drug because of CMV antigen or DNA detection, end-organ disease, or any other cause. Patients underwent weekly surveillance for CMV infection.
Results: The reduction in the incidence of all-cause prophylaxis failure was dose-dependent. The incidence of prophylaxis failure with letermovir, as compared with placebo, was 48% versus 64% at a daily letermovir dose of 60 mg (P=0.32), 32% at a dose of 120 mg (P=0.01), and 29% at a dose of 240 mg (P=0.007). Kaplan-Meier time-to-onset profiles for prophylaxis failure showed a significant difference in the comparison of letermovir at a dose of 240 mg per day with placebo (P=0.002). The safety profile of letermovir was similar to placebo, with no indication of hematologic toxicity or nephrotoxicity.
Conclusions: Letermovir, as compared with placebo, was effective in reducing the incidence of CMV infection in recipients of allogeneic hematopoietic-cell transplants. The highest dose (240 mg per day) had the greatest anti-CMV activity, with an acceptable safety profile. (Funded by AiCuris; ClinicalTrials.gov number, NCT01063829.).
Source: PubMed